What is Oric Pharmaceuticals, Inc.'s earnings per share (EPS)?

Oric Pharmaceuticals, Inc. (ORIC) reported diluted earnings per share of $-1.47 for fiscal year 2025. This represents a 19.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Oric Pharmaceuticals, Inc. Financials

ORIC

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Oric Pharmaceuticals, Inc. (ORIC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ORIC FY2025 2026-05-04

External financing is sustaining a research-first operating model while reported balance-sheet growth is not showing up as cash.

FY2025 brought financing inflows of $245.3M, pushing total assets to $408.9M. Yet cash finished at only $45.7M, so the stronger balance sheet mainly reflects capital that was redeployed into operations and investments rather than retained as liquidity.

R&D spending of $109.8M was more than triple SG&A at $33.2M, which shows the cost base is still centered on development work rather than commercialization. Low capital intensity also stands out: free cash flow of -$111.7M stayed very close to operating cash flow of -$111.0M, so cash burn came from research and overhead, not big equipment needs.

ROE moved from -52.6% to -33.7%, which looks better mathematically than operationally because new capital enlarged equity. Net loss still ran at -$129.5M, and debt pressure remained limited with total liabilities of $24.5M, so the core issue is funding ongoing development programs rather than servicing borrowings.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Oric Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Oric Pharmaceuticals, Inc. carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 14.13, Oric Pharmaceuticals, Inc. holds $14.13 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Oric Pharmaceuticals, Inc. generates a -33.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -52.6% the prior year.

Piotroski F-Score Weak

3/9

Oric Pharmaceuticals, Inc. passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Oric Pharmaceuticals, Inc. generates $0.86 in operating cash flow (-$111.0M OCF vs -$129.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$141.8M

YoY+0.0%

Oric Pharmaceuticals, Inc.'s EBITDA was -$141.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.0% from the prior year.

Net Income

-$129.5M

YoY-1.3%

Oric Pharmaceuticals, Inc. reported -$129.5M in net income in fiscal year 2025. This represents a decrease of 1.3% from the prior year.

EPS (Diluted)

$-1.47

YoY+19.7%

Oric Pharmaceuticals, Inc. earned $-1.47 per diluted share (EPS) in fiscal year 2025. This represents an increase of 19.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$111.7M

YoY+1.9%

Oric Pharmaceuticals, Inc. generated -$111.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 1.9% from the prior year.

Cash & Debt

$45.7M

YoY-23.1%

5Y CAGR-10.3%

Oric Pharmaceuticals, Inc. held $45.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

100M

YoY+41.3%

5Y CAGR+22.3%

Oric Pharmaceuticals, Inc. had 100M shares outstanding in fiscal year 2025. This represents an increase of 41.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-33.7%

YoY+18.9pp

5Y CAGR-8.2pp

Oric Pharmaceuticals, Inc.'s ROE was -33.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 18.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$109.8M

YoY-3.7%

5Y CAGR+25.0%

Oric Pharmaceuticals, Inc. invested $109.8M in research and development in fiscal year 2025. This represents a decrease of 3.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$712K

YoY-40.1%

5Y CAGR+1.3%

Oric Pharmaceuticals, Inc. invested $712K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 40.1% from the prior year.

ORIC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$109.8M-3.7%	$114.1M+33.9%	$85.2M+38.1%	$61.7M+8.5%	$56.9M+58.3%	$35.9M
SG&A Expenses	$33.2M+15.1%	$28.8M+12.6%	$25.6M+2.1%	$25.1M+14.0%	$22.0M+64.0%	$13.4M
Operating Income	-$143.0M-0.1%	-$142.9M-29.0%	-$110.8M-20.7%	-$91.8M-16.4%	-$78.9M-6.3%	-$74.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$129.5M-1.3%	-$127.8M-27.0%	-$100.7M-13.0%	-$89.1M-13.2%	-$78.7M-6.8%	-$73.7M
EPS (Diluted)	$-1.47+19.7%	$-1.83+6.6%	$-1.96+12.9%	$-2.25-8.7%	$-2.07	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$31.4M	N/A	$28.8M-5.8%	$30.5M+24.0%	$24.6M	N/A	$31.2M+7.8%	$28.9M
SG&A Expenses	$8.2M	N/A	$7.9M-7.2%	$8.5M+5.4%	$8.1M	N/A	$7.1M+0.6%	$7.1M
Operating Income	-$39.6M	N/A	-$36.7M+6.1%	-$39.1M-19.4%	-$32.7M	N/A	-$38.3M-6.4%	-$36.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$35.8M	N/A	-$32.6M+10.4%	-$36.4M-21.1%	-$30.0M	N/A	-$34.6M-8.1%	-$32.0M
EPS (Diluted)	$-0.34	N/A	$-0.33+29.8%	$-0.47-11.9%	$-0.42	N/A	$-0.49-8.9%	$-0.45

ORIC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$408.9M+49.2%	$274.1M+8.8%	$252.0M+2.0%	$247.2M-17.2%	$298.6M-0.1%	$299.0M
Current Assets	$288.5M+10.0%	$262.3M+23.4%	$212.6M+1.0%	$210.5M-12.5%	$240.5M-18.9%	$296.7M
Cash & Equivalents	$45.7M-23.1%	$59.4M+154.0%	$23.4M-65.0%	$66.8M-70.4%	$226.0M+188.1%	$78.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$24.5M-20.9%	$31.0M+11.1%	$27.9M+12.5%	$24.8M-3.3%	$25.7M+178.3%	$9.2M
Current Liabilities	$20.4M-17.8%	$24.8M+21.4%	$20.5M+32.9%	$15.4M+1.6%	$15.2M+68.3%	$9.0M
Long-Term Debt	N/A	N/A	N/A	N/A	$10.5M+1650.0%	$600K
Total Equity	$384.4M+58.1%	$243.1M+8.5%	$224.1M+0.8%	$222.4M-18.5%	$273.0M-5.8%	$289.8M
Retained Earnings	-$692.2M-23.0%	-$562.8M-29.4%	-$434.9M-30.1%	-$334.2M-36.4%	-$245.1M-47.3%	-$166.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$436.8M+6.8%	$408.9M-5.2%	$431.2M+24.3%	$346.9M+42.8%	$242.9M-11.4%	$274.1M-9.2%	$302.1M-8.2%	$328.9M
Current Assets	$290.2M+0.6%	$288.5M-2.4%	$295.6M+1.5%	$291.1M+37.7%	$211.4M-19.4%	$262.3M-6.1%	$279.4M-5.1%	$294.6M
Cash & Equivalents	$56.4M+23.5%	$45.7M-8.1%	$49.7M-34.5%	$75.9M+53.8%	$49.3M-17.0%	$59.4M+34.3%	$44.2M-11.2%	$49.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$21.2M-13.5%	$24.5M+1.1%	$24.3M+6.2%	$22.9M-1.1%	$23.1M-25.5%	$31.0M+10.5%	$28.1M+5.9%	$26.5M
Current Liabilities	$17.8M-13.0%	$20.4M+1.2%	$20.2M+11.8%	$18.1M+2.5%	$17.6M-29.1%	$24.8M+16.9%	$21.2M+8.7%	$19.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$415.6M+8.1%	$384.4M-5.5%	$406.9M+25.6%	$324.0M+47.4%	$219.7M-9.6%	$243.1M-11.3%	$274.0M-9.4%	$302.4M
Retained Earnings	-$728.0M-5.2%	-$692.2M-4.6%	-$661.7M-5.2%	-$629.1M-6.1%	-$592.8M-5.3%	-$562.8M-6.9%	-$526.5M-7.0%	-$491.9M

ORIC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$111.0M+1.5%	-$112.7M-31.5%	-$85.7M-14.0%	-$75.1M-26.2%	-$59.5M-31.5%	-$45.3M
Capital Expenditures	$712K-40.1%	$1.2M+39.9%	$849K-59.1%	$2.1M+121.3%	$939K+40.8%	$667K
Free Cash Flow	-$111.7M+1.9%	-$113.8M-31.6%	-$86.5M-12.1%	-$77.2M-27.7%	-$60.5M-31.7%	-$45.9M
Investing Cash Flow	-$148.0M-768.7%	$22.1M+151.0%	-$43.4M+60.3%	-$109.2M-169.0%	$158.4M+173.4%	-$216.0M
Financing Cash Flow	$245.3M+93.8%	$126.5M+47.7%	$85.7M+239.6%	$25.2M-48.7%	$49.1M-80.4%	$250.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$32.4M-44.3%	-$22.5M+10.5%	-$25.1M+18.6%	-$30.8M+5.2%	-$32.5M-16.0%	-$28.1M+2.6%	-$28.8M-12.4%	-$25.6M
Capital Expenditures	$2K-99.1%	$227K+548.6%	$35K-44.4%	$63K-83.7%	$387K+76.7%	$219K-47.6%	$418K+25.5%	$333K
Free Cash Flow	-$32.4M-42.8%	-$22.7M+9.7%	-$25.1M+18.6%	-$30.9M+6.1%	-$32.9M-16.4%	-$28.3M+3.2%	-$29.2M-12.5%	-$26.0M
Investing Cash Flow	-$18.0M-205.8%	$17.0M+115.4%	-$110.5M-43.7%	-$76.9M-442.7%	$22.4M-47.4%	$42.7M+84.9%	$23.1M+26.2%	$18.3M
Financing Cash Flow	$61.1M+3976.0%	$1.5M-98.6%	$109.5M-18.5%	$134.3M+1220827.3%	$11K-98.1%	$575K+356.3%	$126K-84.6%	$816K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ORIC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-33.7%+18.9pp	-52.6%-7.7pp	-44.9%-4.9pp	-40.1%-11.2pp	-28.8%-3.4pp	-25.4%
Return on Assets	-31.7%+15.0pp	-46.6%-6.7pp	-40.0%-3.9pp	-36.1%-9.7pp	-26.4%-1.7pp	-24.6%
Current Ratio	14.13+3.6	10.55+0.2	10.39-3.3	13.68-2.2	15.88-17.1	32.96
Debt-to-Equity	0.06-0.1	0.130.0	0.12+0.0	0.11+0.1	0.04+0.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-8.6%	N/A	-8.0%+3.2pp	-11.2%+2.4pp	-13.7%	N/A	-12.6%-2.1pp	-10.6%
Return on Assets	-8.2%	N/A	-7.6%+2.9pp	-10.5%+1.9pp	-12.4%	N/A	-11.4%-1.7pp	-9.7%
Current Ratio	16.33+2.2	14.13-0.5	14.65-1.5	16.13+4.1	12.00+1.4	10.55-2.6	13.15-1.9	15.08
Debt-to-Equity	0.05-0.0	0.060.0	0.06-0.0	0.07-0.0	0.11-0.0	0.13+0.0	0.10+0.0	0.09
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nuvation Bio Inc NUVB

$1.6B

Maze Therapeutics MAZE

$1.4B

Rapport Therapeutics Inc RAPP

$1.7B

Enliven Therapeutics Inc ELVN

$2.5B

Frequently Asked Questions

Is Oric Pharmaceuticals, Inc. profitable?

No, Oric Pharmaceuticals, Inc. (ORIC) reported a net income of -$129.5M in fiscal year 2025.

What is Oric Pharmaceuticals, Inc.'s EBITDA?

Oric Pharmaceuticals, Inc. (ORIC) had EBITDA of -$141.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Oric Pharmaceuticals, Inc.'s return on equity (ROE)?

Oric Pharmaceuticals, Inc. (ORIC) has a return on equity of -33.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Oric Pharmaceuticals, Inc.'s free cash flow?

Oric Pharmaceuticals, Inc. (ORIC) generated -$111.7M in free cash flow during fiscal year 2025. This represents a 1.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Oric Pharmaceuticals, Inc.'s operating cash flow?

Oric Pharmaceuticals, Inc. (ORIC) generated -$111.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Oric Pharmaceuticals, Inc.'s total assets?

Oric Pharmaceuticals, Inc. (ORIC) had $408.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Oric Pharmaceuticals, Inc.'s capital expenditures?

Oric Pharmaceuticals, Inc. (ORIC) invested $712K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Oric Pharmaceuticals, Inc. spend on research and development?

Oric Pharmaceuticals, Inc. (ORIC) invested $109.8M in research and development during fiscal year 2025.

How many shares does Oric Pharmaceuticals, Inc. have outstanding?

Oric Pharmaceuticals, Inc. (ORIC) had 100M shares outstanding as of fiscal year 2025.

What is Oric Pharmaceuticals, Inc.'s current ratio?

Oric Pharmaceuticals, Inc. (ORIC) had a current ratio of 14.13 as of fiscal year 2025, which is generally considered healthy.

What is Oric Pharmaceuticals, Inc.'s debt-to-equity ratio?

Oric Pharmaceuticals, Inc. (ORIC) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Oric Pharmaceuticals, Inc.'s return on assets (ROA)?

Oric Pharmaceuticals, Inc. (ORIC) had a return on assets of -31.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Oric Pharmaceuticals, Inc.'s cash runway?

Based on fiscal year 2025 data, Oric Pharmaceuticals, Inc. (ORIC) had $45.7M in cash against an annual operating cash burn of $111.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Oric Pharmaceuticals, Inc.'s Piotroski F-Score?

Oric Pharmaceuticals, Inc. (ORIC) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Oric Pharmaceuticals, Inc.'s earnings high quality?

Oric Pharmaceuticals, Inc. (ORIC) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Oric Pharmaceuticals, Inc.?

Oric Pharmaceuticals, Inc. (ORIC) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.